Edwards Lifesciences Corporation
NYSE:EWMedical - Devices
+$0.49 today
- Market cap
- $60.51B
- Beta
- 0.87
- P/E (TTM)
- 46.2
- EPS (TTM)
- $1.89
Volume 3.92M
Average 5.02M
EW Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Edwards Lifesciences CorporationNYSE: EW
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $278.9M rose 1.0% year over year, behind the +3.3% change in trailing-twelve-month research & development. Sequentially, it rose 5.9% from the prior quarter. Over 3 fiscal years it compounded at +4.5% a year.
Context
- Research & development amounted to 17.8% of revenue in FY2025, down 1.6 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +1.0% toward the trailing-twelve-month pace of +3.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 1.08B USD
- Year-over-year change
- +2.5%
- 4-year CAGR
- +4.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.08B | +2.5% |
| FY2024 | 2024-12-31 | 1.05B | +9.4% |
| FY2023 | 2023-12-31 | 962.9M | +1.9% |
| FY2022 | 2022-12-31 | 945.2M | +4.7% |
| FY2021 | 2021-12-31 | 903.1M | — |
Research & Development vs competitors
How EW compares with its peers on the latest reported figures
- EW's LTM Jun 2026 research & development of $1.09B is the 2nd highest of the 6 companies compared; the peer median is $92.25M.
- Its year-over-year change of +3.3% is the 5th highest of 6, against a peer median of +17.2%.
- Research & development amounts to 16.7% of revenue for EW, versus a peer median of 12.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.49B | +19.2% | +14.3% | 12.9% | |
| LTM Jun 2026 | $1.09B | +3.3% | +4.5% | 16.7% | |
| LTM Sep 2026 | $202.57M | +14.5% | +6.0% | 13.4% | |
| LTM Jun 2026 | $92.25M | +1.9% | +4.2% | 6.1% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $70.12M | +24.4% | +57.8% | 3788.3% |
| LTM Mar 2026 | $33.1M | +17.2% | -7.3% | 7.2% | |
| Peer median (excluding EW) | $92.25M | +17.2% | +6.0% | 12.9% | |
Competitors are the stored peer set for EW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.23B | 5.38B | 5.01B | 5.44B | 6.07B |
| Cost of Revenue | 1.23B | 1.17B | 1.04B | 1.12B | 1.33B |
| Gross Profit | 4.01B | 4.22B | 3.97B | 4.32B | 4.74B |
| Gross Margin | 76.6% | 78.3% | 79.3% | 79.5% | 78.1% |
| Research & Development | 903.1M | 945.2M | 962.9M | 1.05B | 1.08B |
| Selling, General & Admin | 1.49B | 1.57B | 1.58B | 1.79B | 2.09B |
| Operating Expenses | 2.4B | 2.51B | 2.55B | 2.94B | 3.1B |
| Depreciation & Amortization | 134.8M | 139.6M | 144.9M | 155.2M | 156.6M |
| EBITDA | 1.86B | 1.93B | 1.53B | 1.72B | 1.43B |
| EBITDA Margin | 35.6% | 35.9% | 30.6% | 31.7% | 23.6% |
| Operating Income | 1.61B | 1.7B | 1.43B | 1.38B | 1.64B |
| Operating Margin | 30.8% | 31.6% | 28.5% | 25.3% | 27.0% |
| Interest Income | 17.4M | 35.5M | 67.2M | 120.3M | 148.4M |
| Interest Expense | 24.8M | 26.2M | 17.6M | 19.8M | 0 |
| Other Income / Expenses | 91.6M | 65M | (54.9M) | 169.4M | (363.3M) |
| Income Before Tax | 1.7B | 1.77B | 1.37B | 1.55B | 1.27B |
| Pre-Tax Margin | 32.5% | 32.8% | 27.4% | 28.5% | 21.0% |
| Income Tax Expense | 198.9M | 245.5M | 152.4M | 152.1M | 216.9M |
| Net Income | 1.5B | 1.52B | 1.4B | 4.17B | 1.07B |
| Net Margin | 28.7% | 28.3% | 28.0% | 76.7% | 17.7% |
| EPS (Basic) | 2.41 | 2.46 | 2.31 | 6.98 | 1.84 |
| EPS (Diluted) | 2.38 | 2.44 | 2.30 | 6.97 | 1.83 |
| Weighted Avg Shares | 623.3M | 619M | 606.7M | 597.7M | 584.8M |
| Weighted Avg Shares (Diluted) | 631.2M | 624.2M | 609.4M | 599.3M | 585.8M |
Edwards Lifesciences Corporation
NYSE:EW
Intrinsic Alpha fair value
Locked
Current Price
$105.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.